Multiple Sclerosis Drugs - Argentina

Argentina

Argentina is projected to see a revenue of €69.27m in 2024 in the Multiple Sclerosis Drugs market.
The market is expected to grow at an annual growth rate (CAGR 2024-2029) of 0.54%, leading to a market volume of €71.17m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of €10,800.00m in 2024.
The demand for multiple sclerosis drugs in Argentina is on the rise, driven by increased awareness and improved access to treatment options.

Key regions: France, India, United Kingdom, South Korea, Japan

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Multiple Sclerosis Drugs market in Argentina has been showing promising growth in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in Argentina prefer treatments that are affordable and effective. They also value drugs that cause minimal side effects. Moreover, they prefer treatments that are easy to administer and do not require frequent visits to the hospital.

Trends in the market: The Multiple Sclerosis Drugs market in Argentina has been growing due to the increasing prevalence of Multiple Sclerosis in the country. The market has been witnessing a shift towards the use of oral drugs as they are considered more convenient than injectable drugs. Additionally, the market has been witnessing the introduction of new drugs that are more effective and have fewer side effects.

Local special circumstances: The healthcare system in Argentina is highly fragmented, and access to healthcare services varies significantly across the country. The availability of drugs and medical facilities is limited in rural areas, which makes it difficult for patients living in these areas to access treatment. Additionally, the high cost of drugs makes it difficult for low-income patients to afford treatment.

Underlying macroeconomic factors: The economic situation in Argentina has been unstable in recent years, with high inflation rates and currency devaluation. This has led to a decrease in purchasing power, making it difficult for patients to afford expensive drugs. The government has been implementing policies to improve access to healthcare services and reduce the cost of drugs. However, the implementation of these policies has been slow, and there is still a long way to go to improve the healthcare system in the country.In conclusion, the Multiple Sclerosis Drugs market in Argentina has been growing due to the increasing prevalence of the disease and the introduction of new drugs. However, the high cost of drugs and the limited access to healthcare services in certain areas pose significant challenges to the market. The government needs to implement policies to improve access to healthcare services and reduce the cost of drugs to ensure that patients have access to the treatments they need.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.